Exact Sciences Corporation with ticker code (EXAS) have now 18 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between 100 and 70.3 suggesting an average Analsyt target price of $86.52. Given that the stocks previous close was at $83.61 this is indicating there is a potential upside of 3.5%. The 50 day MA is $68.71 and the 200 moving average now moves to $52.81. The market cap for the company is 14.79B. The stock price for Iron Mountain Incorporated is 82 USD
The potential market cap would be $15,306,637,208 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of 12.4 and a -4.92% return on assets.
Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company’s products include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test and COVID-19 Testing. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
